Cabozantinib for Patients With Recurrent or Progressive Meningioma

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

May 31, 2028

Conditions
Meningioma
Interventions
DRUG

Cabozantinib

Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.

Trial Locations (3)

33176

RECRUITING

Miami Cancer Institute at Baptist Health, Inc., Miami

37232

RECRUITING

Vanderbilt University Medical Center, Nashville

100653

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Exelixis

INDUSTRY

lead

Baptist Health South Florida

OTHER

NCT05425004 - Cabozantinib for Patients With Recurrent or Progressive Meningioma | Biotech Hunter | Biotech Hunter